We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

Fund managers haven’t disclosed any holdings of TAK yet.

TAK Hedge Fund Activity: Q1 2026 in Review

359 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2026, worth a combined $1.82B — up 39% from $1.31B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new TAK positions and 38 closed out — a net gain of 18 holders — while 174 added to existing stakes and 58 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $113M. The largest seller was Arrowstreet Capital, cutting an estimated $45M.

  • 359 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2026, up from 349 in Q4 2025.
  • Funds reported $1.82B of Takeda Pharmaceutical stock for Q1 2026, up 39% quarter-over-quarter.
  • 56 funds opened new Takeda Pharmaceutical positions in Q1 2026 and 38 closed out, a net change of +18 holders.
  • The largest Takeda Pharmaceutical buyer in Q1 2026 was Adage Capital Partners, an estimated $113M added.
  • The largest Takeda Pharmaceutical seller in Q1 2026 was Arrowstreet Capital, an estimated $45M sold.

Based on aggregated 13F filings for Q1 2026.